Poxel Revenue Dips 25% in 2025 Amid Judicial Reorganization Exit

Event summary

  • Poxel reported €5 million in 2025 revenue, down 25% from €6.6 million in 2024, which included a ¥500 million milestone payment from Sumitomo.
  • Royalties from TWYMEEG® sales in Japan totaled €4.5 million, with a retroactive adjustment adding €480,000.
  • Cash reserves shrank to €0.9 million by year-end, down from €3.7 million in Q4 2024.
  • Poxel exited judicial reorganization proceedings on January 22, 2026, following court approval of its continuation plan.

The big picture

Poxel’s revenue decline reflects the absence of 2024’s milestone payment, highlighting its reliance on Sumitomo’s TWYMEEG® sales. The company’s exit from judicial reorganization marks a pivotal but precarious phase, as it seeks to stabilize finances while advancing pipeline therapies. The strategic partnership with Sumitomo remains critical, though cash constraints could limit operational flexibility.

What we're watching

Royalty Growth
Whether Poxel can sustain double-digit royalty growth from TWYMEEG® sales in 2026 as projected.
Cash Burn
The pace at which Poxel depletes its remaining cash reserves amid ongoing restructuring.
Debt Redemption
How OrbiMed’s royalty monetization agreement will impact Poxel’s debt obligations.

Related topics

Restructuring